Sauveur-Michel Maira

Author

Novartis (Switzerland)ORCID

Also Known As

Maira Sauveur-Michel, Maira, S, Michel Maira, S M Maira, S Maira, S. M. Maira, S.M. Maira, Sauveur-Michel Maira

254

Publications

7.3K

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research Novartis (United States)Inserm Centre National de la Recherche Scientifique

About

Sauveur-Michel Maira is an author at Novartis (Switzerland) specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	4K
2	Natural Sciences	12	12	1.9K
3	Biochemistry	4	4	378
4	Health Sciences	2	2	1K
5	Biomolecular Engineering	2	2	772

Sauveur-Michel Maira

Publications

Citations

H-Index

Page 1

	Year	Citations
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Molecular Cancer Therapeutics	2008	1.1K
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations Anna Dubrovska, Sungeun Kim, Richard J. Salamone, Proceedings of the National Academy of Sciences Lineage PlasticityDevelopmental BiologyPi3k ActivityHealth SciencesPi3k Signaling	2008	562
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Molecular Cancer Therapeutics PharmacotherapyDifferent Selectivity ProfileChemical BiologyPharmaceutical ChemistryTumor Biology	2011	524
Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials Christine Fritsch, Alan Huang, Christian Chatenay‐Rivauday, Molecular Cancer Therapeutics Pten MutationSomatic Pik3ca MutationsPharmacotherapyCancer BiologyTumor Biology	2014	462
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells Saskia M. Brachmann, Irmgard Hofmann, Christian Schnell, Proceedings of the National Academy of Sciences Dual Pi3k/mtor InhibitorBreast OncologyOncologyApoptosis InductionMedicine	2009	316
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer Todd W. Miller, Justin M. Balko, Emily M. Fox, Cancer Discovery Breast OncologySirna ScreeningHuman Breast CancerCancer BiologyMammary Gland Development	2011	315
Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane Sauveur-Michel Maira, Ivana Galetić, Derek P. Brazil, Science	2001	261
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor Heidi A. Lane, Jeanette M. Wood, Paul M.J. McSheehy, Clinical Cancer Research	2009	250
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas Ta-Jen Liu, Dimpy Koul, Tiffany A. LaFortune, Molecular Cancer Therapeutics	2009	249
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer Matthew T. Burger, Sabina Pecchi, Allan S. Wagman, ACS Medicinal Chemistry Letters 2,4-Bismorpholino 6-Heterocyclic PyrimidinesPi3 Kinase InhibitorOrally Bioavailable ClassGliomaPharmaceutical Chemistry	2011	248

Page 1